Table 1 Patient characteristics Patient... | American Society of Hematology

Table 1

Patient characteristics

Patient no.	Age, y/sex	Diagnosis	Disease status	Time from diagnosis to transplantation, d	Pretransplantation MF grade	Splenomegaly	Cytogenetics
1	55/M	AML/MF/ET	PIF	1732	3	Yes	Normal
2	53/M	PMF	Untreated	307	3	Yes	NA
3	61/M	AML/MDS	PIF	116	3	Yes	Complex*
4	51/F	AML/MDS	PIF	740	3	Yes	Normal
5	61/F	AML/MDS	PIF	227	3	Yes	NA
6	55/M	AML/MDS	Untreated	299	3	Yes	Complex
7	46/M	AML/MDS	Untreated	600	3	Yes	NA
8	58/M	AML/MDS	Untreated	544	3	Yes	Complex
9	67/F	AML/MF/PV	Untreated	150	3	Yes	t(3;3)(q21;q26), −7
10	53/M	De novo AML	PIF	111	3	No	Complex
11	57/F	AML/MDS	Untreated	352	3	Yes	Complex with t(9;22)(q34;q11)
12	62/M	AML/MDS	Untreated	147	3	Yes	add(1)(p32), −7
13	72/F	AML/MDS	PIF	329	2	No	Complex with t(9;22)(q34;q11)
14	66/M	AML/MDS	Untreated	92	3	No	Normal

Patient no.	Age, y/sex	Diagnosis	Disease status	Time from diagnosis to transplantation, d	Pretransplantation MF grade	Splenomegaly	Cytogenetics
1	55/M	AML/MF/ET	PIF	1732	3	Yes	Normal
2	53/M	PMF	Untreated	307	3	Yes	NA
3	61/M	AML/MDS	PIF	116	3	Yes	Complex*
4	51/F	AML/MDS	PIF	740	3	Yes	Normal
5	61/F	AML/MDS	PIF	227	3	Yes	NA
6	55/M	AML/MDS	Untreated	299	3	Yes	Complex
7	46/M	AML/MDS	Untreated	600	3	Yes	NA
8	58/M	AML/MDS	Untreated	544	3	Yes	Complex
9	67/F	AML/MF/PV	Untreated	150	3	Yes	t(3;3)(q21;q26), −7
10	53/M	De novo AML	PIF	111	3	No	Complex
11	57/F	AML/MDS	Untreated	352	3	Yes	Complex with t(9;22)(q34;q11)
12	62/M	AML/MDS	Untreated	147	3	Yes	add(1)(p32), −7
13	72/F	AML/MDS	PIF	329	2	No	Complex with t(9;22)(q34;q11)
14	66/M	AML/MDS	Untreated	92	3	No	Normal

AML indicate acute myeloid leukemia; MF, myelofibrosis; ET, essential thrombocythemia; PIF, primary induction failure; PMF, primary myelofibrosis; AML/MDS, acute myeloid leukemia with multilineage dysplasia; NA, not available; and PV, polycythemia vera.

Complex karyotype was defined as 3 or more abnormalities at pretransplantation evaluation.

View Large